Detailseite
Projekt Druckansicht

'Theranostischer' Ansatz unter Verwendung eines 'Trojanischen Pferdes' bei Atherosklerose.

Antragsteller Dr. Kai-Uwe Jarr
Fachliche Zuordnung Kardiologie, Angiologie
Förderung Förderung von 2018 bis 2020
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 397504785
 
Erstellungsjahr 2021

Zusammenfassung der Projektergebnisse

The accumulation of apoptotic cells in the necrotic core plays a pivotal role in atherosclerotic plaques. The pathological upregulation of a “don’t eat me” molecule known as CD47 leads to defective programmed cell removal. Pro-phagocytic therapies, such as anti-CD47 antibodies, have been used to stimulate the phagocytic clearance of apoptotic cells. However, the clearance of red blood cells which results in anaemia might limit the translational potential of the antibody-based strategy. Here we developed a macrophage-specific nanotherapy based on single-walled carbon nanotubes loaded with a chemical inhibitor of signal-regulatory protein alpha’s (SIRPα) downstream effector molecule Src homology 2 domain-containing phosphatase-1 (SHP-1). This „Trojan horse“-system, which targets the anti-phagocytic CD47-SIRPα signalling axis, reactivated efferocytosis locally and prevented atherosclerosis without inducing a significant on-target or off-target toxicity in apolipoprotein E-deficient mice. Additionally, single-cell RNA sequencing revealed an anti-inflammatory signature in those modulated, nanoparticle-exposed macrophages. Taken together, our approach of using macrophage-specific nanoparticles represents a significant advance for this class of drugs.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung